Why these two injections are rarely competing options

Most patients searching for knee injection options arrive at ChondroFiller and Arthrosamid with the same question: which one works better? It is the wrong question — and understanding why changes the entire decision.

These two treatments do not compete for the same problem. ChondroFiller is a collagen scaffold injected into a discrete, focal defect at the cartilage surface covering the bone ends of the knee. Arthrosamid is a hydrogel that integrates into the synovial lining — the soft-tissue capsule surrounding the joint — acting as a permanent mechanical cushion for the generalised cartilage loss of osteoarthritis. One acts at the bone surface; the other acts at the joint lining. Anatomically, they are working in different places on a different kind of damage.

The practical consequence is direct: a patient with a small, well-defined cartilage lesion from a sports injury is not a candidate for Arthrosamid, and a patient with widespread knee osteoarthritis across multiple compartments is not a suitable candidate for ChondroFiller. Choosing the wrong treatment — or framing the decision as a ranking exercise — risks neither working as intended.

No head-to-head randomised trial exists between them, and this is not a gap in the evidence. It reflects that they treat different diagnoses. What determines the pathway is imaging: weight-bearing X-rays to characterise joint space and degeneration, and an MRI to identify whether the damage is focal or diffuse. The scan answers the question before any product discussion begins.

What ChondroFiller does and who it suits

ChondroFiller is a CE-marked Class III medical device — a murine-derived Type I collagen scaffold delivered by ultrasound-guided injection in an outpatient clinic, under local anaesthesia, in a single appointment. Once placed inside a focal cartilage defect, the gel forms in situ within 3–5 minutes and bonds to the surrounding cartilage walls.

The mechanism is called acellular matrix-induced chondrogenesis. The scaffold contains no cells and no drugs; instead, it supports the body's own repair processes by providing a 3D matrix into which the patient's own progenitor cells migrate from the neighbouring synovium and subchondral bone. A 2025 ex vivo study measured a 2.4-fold increase in DNA content within the scaffold by day 14, demonstrating active cellular recruitment. Over the following months, the scaffold biodegrades progressively as new repair tissue forms in its place.

Clinically, four knee studies have recorded IKDC score improvements consistently above the 16.7-point minimum clinically important difference. The Jerosch prospective PMCF study reported a mean gain of 32.4 IKDC points sustained at three years, with patients reaching a functional score of 80. Structural MRI shows MOCART scores of 81.6–84.3, indicating greater than 80% defect fill, and published series report 70–85% pain relief at five years.

The ideal candidate is a younger-to-middle-aged, active adult with a focal Grade III or IV cartilage defect smaller than 2 cm², typically arising from a sports injury or trauma, in a joint that is otherwise largely healthy. If your MRI shows this kind of well-defined, contained lesion, ChondroFiller may be a fitting pathway.

The key contraindication is background osteoarthritis. When generalised OA is already present across the joint, published evidence shows outcomes are significantly worse — this is clinically critical for self-triage. Rehabilitation commitment is also substantial: a structured three-phase physiotherapy programme (Protect, Strengthen, Return to activity) spanning several months is required to protect the developing repair tissue.

What Arthrosamid does and who it suits

Delivered as a single 6 mL outpatient injection and CE-approved in 2021, Arthrosamid is a 2.5% cross-linked polyacrylamide gel in 97.5% sterile water — a formulation referred to as iPAAG, manufactured by Contura International Ltd specifically for the treatment of knee osteoarthritis.

The mechanism is mechanical, not regenerative. After injection, the hydrogel migrates sub-synovially over 10–14 days, integrating into the inner lining of the joint capsule as a permanent, non-biodegradable cushion. This reduces load transmitted across a degenerated joint and is thought to dampen pain arising from that loading. The gel does not biodegrade and the body lays down no new cartilage as a result of the injection — that is not what it is designed to achieve.

The primary clinical evidence comes from Bliddal et al., whose IDA open-label study enrolled 49 participants with a mean age of 70. A single 6 mL treatment maintained its effect at 13, 26, and 52 weeks with no significant adverse events. A 12-month peer-reviewed follow-up published in the Journal of Orthopaedic Surgery and Research (2024, cited 25 times) confirmed that durability. Long-term safety monitoring has not identified significant complications from permanent intra-articular residence — and, unlike repeated corticosteroid injections, no detrimental effect on cartilage has been associated with its use.

The ideal candidate is typically an older patient with established knee osteoarthritis of Kellgren–Lawrence Grade II to IV, where cartilage loss is generalised across one or more compartments rather than confined to a focal lesion. The primary goal is sustained pain relief and surgical delay, not structural repair. Recovery is comparatively light: 10–14 days of relative rest is all that is ordinarily required after injection.

That Arthrosamid does not address underlying cartilage loss is not a limitation in this context — it is the correct treatment for a condition where focal regeneration is neither possible nor the aim.

Which knee diagnosis points to which treatment

The genuinely difficult question is not which treatment to choose when the diagnosis is clear — by this point, that logic is apparent. The harder question arises when your MRI shows a focal lesion sitting inside a joint that also carries some background osteoarthritic change. That overlap is common, and it is where self-triage breaks down.

When focal damage and diffuse degeneration coexist, neither product is straightforwardly indicated. ChondroFiller is designed for an otherwise structurally sound joint; Arthrosamid addresses widespread joint degeneration rather than a discrete surface lesion. A knee that has both features may not be well served by either in isolation, or may require a staged or combined approach that only a specialist assessment can determine.

For cases that sit clearly on one side of the line, the framework is this: a single, well-defined, MRI-confirmed focal lesion in a joint free of diffuse OA points toward the ChondroFiller pathway, particularly in a younger or more active patient whose damage arose from sport or injury. Generalised cartilage loss across one or more compartments — Kellgren–Lawrence Grade II to IV — points toward Arthrosamid, where the goal is sustained pain management rather than structural repair.

Neither product can be selected on symptoms alone. Both require weight-bearing X-rays and MRI to characterise the lesion pattern, grade the surrounding joint, and confirm the structural picture. That imaging step is what separates an appropriate match from a misapplied treatment — and it is also what rules out an overlap scenario that would otherwise only become apparent after injection.

Neither treatment is currently NHS-funded in the UK; both sit within a private assessment and treatment pathway. Lincolnshire Knee accepts patients without a referral — an onMRI™ knee scan and consultant review at the Sleaford or Grantham clinic will establish which, if any, injection pathway fits your specific imaging.

Recovery, onset, and how long each treatment lasts

The practical timelines diverge sharply, and that difference is worth knowing before an appointment is booked.

ChondroFiller works slowly by design. The scaffold recruits progenitor cells in the first weeks after injection, but the repair tissue takes months to mature; meaningful improvements in pain and function typically emerge between six and twelve months. The structured physiotherapy programme outlined earlier in this article is essential throughout — without it, the developing repair tissue is unprotected during the most vulnerable phase of healing. Long-term data suggest 70–85% pain relief at five years, with functional scores sustained above baseline at three years, as discussed in the ChondroFiller outcomes section above.

Arthrosamid's timeline is different in almost every respect. Sub-synovial integration is complete within 10–14 days, and clinical relief can begin anywhere from a matter of hours to around twelve weeks post-injection. No intensive rehabilitation is required afterwards — relative rest during that short integration window is all that is ordinarily asked of the patient. Durability from a single injection is generally described as two to five years, though data beyond the two-to-three-year mark are still maturing.

Neither treatment involves surgery, general anaesthesia, or a theatre admission. Both are outpatient, ultrasound-guided injection appointments — the clinical encounter for each is measured in minutes, not hours. What differs is what happens afterwards: one pathway demands months of supervised rehabilitation to protect the biological repair; the other asks only for a brief period of reduced activity before normal life resumes.

Getting an accurate knee diagnosis before you choose

By this point in the article, the clinical logic is clear: the right treatment is the one that matches the structural reality of your knee — and that reality only becomes visible on imaging.

Knowing which side of the focal-versus-diffuse divide your knee sits on changes what a specialist can offer. An experienced clinician, reviewing a knee MRI and weight-bearing X-rays together, can also identify the overlap cases — where standard selection criteria do not apply cleanly, and where a staged or combined approach may be more appropriate than either product alone. The assessment, in other words, does not just confirm an injection choice; it may open routes neither this article nor a symptom checklist could anticipate.

Lincolnshire Knee offers consultant-led knee assessments at two sites — Sleaford NG34 and Grantham NG31 — without the need for a GP referral and without NHS-style waiting times. Where cartilage characterisation matters, onMRI™ AI-driven analysis — including cartilage segmentation and T2 mapping — can add a layer of precision to what the scan shows, helping to determine which pathway, if any, fits the actual imaging picture.

Book a knee assessment at lincolnshireknee.co.uk.